Treatment of advanced gastric cancer with oral etoposide, leucovorin and tegafur: Experience with an oral modification of the etoposide, leucovorin and 5-fluorouracil (ELF) regimen

European Journal of Cancer

Volumn 34, Issue 7, 1998, Pages 1128-1130

  Raderer, M ^a   Kornek, G V ^a   Hejna, M H L ^a   Miholic, J ^a   Weinlaender, G ^a   Brodowicz, T ^a   Fiebiger, W C C ^a   Valencak, J B ^a   Scheithauer, W ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chemotherapy; Etoposide; Gastric cancer; Leucovorin; Tegafur

Indexed keywords

ETOPOSIDE; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; FTORALON; TEGAFUR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ETOPOSIDE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME;

EID: 0032101814     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10140-X     Document Type: Article

References (13)

1. Boring C. C., Squires T. S., Tong T., Montgomery S. Cancer statistics. CA Cancer J Clin. 44:1994;19-36.
2. Wilke H, Preusser P, Fink U, et al. New developments in the treatment of gastric carcinoma. Semin Oncol 1990, 1, 61-70.
3. Van Cutsem E, Filez L, Dewyspelaere J, et al. Etoposide, leucovorin and 5-fluorouracil in advanced gastric cancer: a phase II study. Anticancer Res 1995, 15, 1079-1080.
4. Taal BG, Teller FG, Bokkel Huinink WW ten, et al. Etoposide, leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide. Ann Oncol 1994, 5, 90-92.
5. Sobrero A. F., Aschele C., Bertino J. R. Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J Clin Oncol. 15:1997;368-381.
6. Anttila MI, Slotaniemi EA, Kairaluoma MI, et al. Pharmacokinetics of Ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol 1983, 10, 150-153.
7. Liu G., Franssen E., Fitch M. I., Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 15:1997;110-115.
8. Scheithauer W, Kornek GV, Hejna M, et al. Palliative chemotherapy versus best supportive care in patients with metastatic gastric cancer: a randomized trial. Ann Hematol 1996, 73(Suppl. II), A-181 (abstract).
9. Glimelius B, Ekström K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997, 8, 163-168.
10. Ajani J, Dumas P, Pazdur R, et al. Phase II trial of oral etoposide in untreated patients with advanced gastric carcinoma. Proc Am Soc Clin Oncol 1993, 12, 217 (abstract).
11. Medical Research Council Lung Cancer Working Party. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small cell lung cancer: a stopped multicentre randomised trial. Lancet 1996, 348, 563-566.
12. Frieman M. A., Ignoffo R. J. A review of the United States clinical experience of the fluoropyrimidine, Ftorafur (NSC-148958). Cancer Treat Rev. 7:1980;205-213.
13. Pazdur R, Lassere Y, Rhodes V, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994, 12, 2296-2300.